In vivo pharmacokinetic study of antibody conjugates

The National Institutes of Health intends to award a Firm-Fixed-Price Purchase Order to Jackson Laboratory for an in vivo pharmacokinetic study of antibody conjugates. The study aims to characterize the pharmacokinetics of optimized antibody-lectin conjugates in a model that more closely reflects human physiology. The protocols used will administer the optimized conjugates intravenously in FcRn mice and measure remaining sera concentrations of the conjugates by ELISA. • The study will be conducted using transgenic FcRn mice expressing human Fc neonatal receptor. • The protocols will involve administering the optimized conjugates intravenously and measuring remaining sera concentrations by ELISA. • The goal is to inform predictions of serum half-life and support further development of antiviral antibody-protein conjugates.